RT Journal Article
T1 Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
T2 Eficacia de los pulsos de corticoides en pacientes con síndrome de liberación de citocinas inducido por infección por SARS-CoV-2.
A1 Callejas Rubio, José Luis
A1 Luna Del Castillo, Juan de Dios
A1 de la Hera Fernández, Javier
A1 Guirao Arrabal, Emilio
A1 Colmenero Ruiz, Manuel
A1 Ortego Centeno, Norberto
K1 Coronavirus COVID-19
K1 Cytokine release synddrome
K1 Hemofagocítico
K1 Hemophagocytic
K1 Síndrome de liberación de citocinas
AB Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19. We included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable. In all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival. The early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death.
YR 2020
FD 2020-05-27
LK http://hdl.handle.net/10668/15731
UL http://hdl.handle.net/10668/15731
LA en
LA es
DS RISalud
RD Jul 31, 2025